MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuroprotective agents"

  • 2019 International Congress

    Alleviation of Parkinson’s and Associated Depression using Silymarin in Rotenone induced Mice Model of Parkinson’s Disease

    D. Khatri (Pune, India)

    Objective: The present study was undertaken in order find out the possible neuroprotective and antidepressant potential of Silymarin. The neuroprotective and antidepressant potential was evaluated…
  • 2019 International Congress

    Pre-diagnosis physical activity habits are associated with age of diagnosis and postural instability in Parkinson’s disease

    M. Landers, K. Johnson, S. Johnson, J. Lyle, T. Ormsby, D. Salgo, J. Zorn, A. Murtishaw, A. Salazar, J. Kinney (Las Vegas, NV, USA)

    Objective: To determine if pre-diagnosis exercise and brain-derived neurotrophic factor (BDNF) genotype are predictive of age at diagnosis and severity of balance impairment. Background: Studies…
  • 2019 International Congress

    Park-Ease Trial: A Randomized Controlled Trial to Study the Efficacy of Exercises in Early-Stage Parkinson’s Disease

    R. Swarnakar, S. Wadhwa, S. V, V. Goyal, V. Sreenivas (New Delhi, India)

    Objective: To evaluate the efficacy of exercises in early-stage Parkinson’s Disease by observing improvement in motor symptoms assessed by Unified Parkinson’s Disease Rating Scale (UPDRS)…
  • 2019 International Congress

    Investigation into the causes of reduced caffeine levels in Parkinson’s disease

    MI. de Bartolo, G. Leodori, A. Fabbrini, M. Costanzo, D. Belvisi, A. Conte, S. Manetto, A. Ciogli, C. Villani, A. Berardelli, G. Fabbrini (Rome, Italy)

    Objective: To find out whether PD patients show decreased salivary caffeine levels; to investigate CYP1A2-phenotype and caffeine absorption as possible causes of decreased caffeine levels…
  • 2019 International Congress

    Limitations of Curcumin as a Therapeutic Agent in Rotenone Induced Dopaminergic Neurodegeneration: Insights from Drosophila Model of Parkinson’s Disease

    M. Ayajuddin, SC. Yenisetti (Zunheboto, India)

    Objective: To understand the efficacy of curcumin in rotenone induced Drosophila model of Parkinson’s disease. Background: Parkinson’s disease (PD) is the second most common neurodegenerative…
  • 2019 International Congress

    Neuroprotective effect of Yerba mate (Ilex paraguariensis) in a Drosophila model of Parkinson ’s disease

    P. Ballestero, A. Bernardi, H. Hauche Pedernera, O. Gershanik, N. Muraro, J. Ferrario (Capital Federal, Argentina)

    Objective: To test the neuroprotective capacity of Yerba Mate (YM) in an in vivo model of Parkinson's disease. Background: Parkinson's disease (PD) is caused by the…
  • 2019 International Congress

    Protective effects of β-Nicotinamide Adenine Dinucleotide against motor deficits and dopaminergic neuronal damage in a Parkinson’s disease mouse model

    C. Shan, YL. Gong, QQ. Zhuang, YF. Hou, SM. Wang, ST. Li, JM. Liu (Shanghai, China)

    Objective: The aim of our study is to explore whether nicotinamide adenine dinucleotide (NAD) replenishment could be beneficial on a 6-hydroxydopamine-induced Parkinson’s disease (PD) mouse…
  • 2019 International Congress

    Relationship between serum uric acid and the pattern of striatal dopamine depletion in De Novo Parkinson’s disease

    K. Baik, Y. Lee, S. Chung, H. Yoo, J. Jung, P. Lee (Seoul, Republic of Korea)

    Objective: To investigate the relationship between serum uric acid (UA) and the pattern of striatal dopamine depletion in drug naïve Parkinson’s disease (PD). Background: UA…
  • 2019 International Congress

    Exploring the experience and challenges for PD STAT clinical trial participants: a qualitative study

    T. North, J. Grose, V. Eyre, D. Webb, R. Chapman, A. Foggo, M. Webber, C. Carroll (Plymouth, United Kingdom)

    Objective: This study aims to identify the reasons why people living with Parkinson’s disease (PD) (PwP) became involved with the PD STAT randomised controlled trial…
  • 2019 International Congress

    Increasing chances of detecting a neuroprotective signal in PhI/II PD clinical trials?

    S. Palfi, C. Denot, A. Bousseau, JC. Corvol (Paris, France)

    Objective: Design an early CT program to detect a neuroprotective signal in PD. Background: Attempts to develop PD modifying therapies have been largely disappointing so…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley